AstraZeneca Results Presentation Deck
BioPharmaceuticals: New CVRM
15% growth boosted by Farxiga and EMS
$m
1,500
1,250
1,000
750
500
250
Q1 2018
Q2 2018
Q3 2018
New CVRM
15% growth
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Farxiga Brilinta Diabetes Renal
Total revenue at actual exchange rates; changes
at CER and for Q1 2021, unless stated otherwise.
15
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
$m
750
500
250
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Farxiga
50% growth - the fastest-growing SGLT2i¹ globally
Q1 2019
Q2 2019
Q3 2019
US Europe EROW EMS
Total revenue at actual exchange rates; changes
at CER and for Q1 2021, unless stated otherwise.
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
US +16%
Strong volume growth including
HFrEF2 indication, but offset by
price impact
Europe +36%
Solid volume growth boosted by
initial launch of HFrEF indication
EMs +85%
Benefit from NRDL inclusion in China
and also strong growth elsewhere
1. Sodium-glucose co-transporter 2 inhibitor 2. Heart failure with reduced
ejection fraction.
ĄView entire presentation